logo

For the Inventor, By the Inventor

Fanwood, NJ, United States of America

Helen M Organ

This inventor holds 6 USPTO granted patents. Top assignee: Merck + Co., Inc.. Active years: 1993-1999.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Helen M Organ. Retrieved from https://idiyas.com/inventor/helen-m-organ

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 6

% Patents Active = 100.0

Average Co-Inventor Count = 3.8

ph-index = 4

Forward Citations = 65(Granted Patents)


Location History:

  • Roselle Park, NJ (US) (1993 - 1994)
  • Fanwood, NJ (US) (1996 - 1999)

Company Filing History:

goldMedal6 out of 4,770 
 
Merck + Co., Inc.
 patents

Years Active: 1993-1999

Loading Chart...
6 patents (USPTO):Explore Patents
1. 5880280 - Aryl, alkyl, alkenyl and alkynylmacrolides having immunosuppressive (1999-03-09),
2. 5693648 - O-aryl, O-alkyl, O-alkenyl and O-alkynyl-macrolides having (1997-12-02),
3. 5565560 - O-Aryl,O-alkyl,O-alkenyl and O-alkynylmacrolides having (1996-10-15),
4. 5532248 - O-aryl,O-alkyl, and O-alkenyl-macrolides having immunosuppressive (1996-07-02),
5. 5284877 - Alkyl and alkenyl macrolides having immunosuppressive activity (1994-02-08),
6. 5262533 - Amino O-aryl macrolides having immunosuppressive activity (1993-11-16),

Title: Helen M Organ: A Pioneer in Immunosuppressive Macrolides Innovation

Introduction

Helen M Organ is an accomplished inventor based in Fanwood, New Jersey. With an impressive portfolio of six patents, she has made significant contributions to the field of immunology through her innovative work on macrolide compounds. Her inventions are not only groundbreaking but also essential in advancing treatment options for various autoimmune diseases and organ transplant procedures.

Latest Patents

Helen's latest patents focus on a novel class of aryl, alkyl, alkenyl, and alkynyl macrolides. These compounds, characterized by specific modifications at critical positions on the cyclohexyl ring, exhibit potent immunosuppressive properties. The macrolide immunosuppressants she developed can be utilized in mammalian hosts for treating autoimmune diseases, infectious diseases, and for preventing organ transplant rejection. This innovative approach has opened new avenues for addressing serious health conditions effectively.

Career Highlights

Throughout her career, Helen has collaborated with leading pharmaceutical companies, including Merck & Company, Inc. and Merck & Co., Inc. Her research and inventions have significantly influenced the direction of immunosuppressive drug development, demonstrating her expertise and commitment to improving patient outcomes through scientific advancement.

Collaborations

Helen has worked alongside esteemed colleagues, including Matthew J Wyvratt and Peter J Sinclair. Their collaboration has fostered a dynamic environment for innovation, contributing to the successful development and implementation of her groundbreaking macrolide compounds.

Conclusion

Helen M Organ's contributions to the field of immunosuppressive agents underscore her role as a leading inventor. Her work not only showcases her individual talent but also highlights the importance of collaboration in driving forward scientific innovation. As the need for effective treatments continues to grow, the significance of her patents will likely have a lasting impact on medical science and patient care.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…